Clinical Trials
5 trialsNCT01154439 2022-10-26
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 1 Completed
NCT02049801 2017-12-06
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT00093483 2014-01-13
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT00331513 2013-09-30
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00107523 2010-09-21
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 1 Completed